Characterization of immunological activity of a low toxicity antitumor lipopolysaccharide from Bordetella pertussis.
Immunological properties of a low toxicity lipopolysaccharide (BP-LPS) extracted from Bordetella pertussis (Tohama strain) which was reported to have high antitumor activity against murine tumors were examined and compared with those of LPS extracted from other enterobacteria. The activation or stimulation of murine macrophages and lymphocytes by these LPS, including TNF induction, was found to be similar. However, BP-LPS was clearly less active in its stimulation of murine and human neutrophils as estimated by neutrophil-adherence assay and by their TNF production than E. coli LPS. Furthermore, BP-LPS also suppressed the activation of human neutrophils by Escherichia coli LPS. A comparative study with 7 LPS preparations indicated that their toxicity in terms of animal body weight loss correlated with their ability to induce human neutrophil adherence. The inability of BP-LPS to activate neutrophils may thus have some bearing on its low toxicity.
Department of Microbiology and Immunology, School of Medicine, Teikyo University, Tokyo, Japan.
M
M
Ohnishi
S
S
Kimura
M
M
Yamazaki
S
S
Abe
H
H
Yamaguchi
D000818:Animals; D000970:Antineoplastic Agents / Q000276:immunology*; D001886:Bordetella pertussis / Q000276:immunology*; D002448:Cell Adhesion; D004926:Escherichia coli / Q000276:immunology; D006801:Humans; D008070:Lipopolysaccharides / Q000276:immunology* / Q000633:toxicity; D008213:Lymphocyte Activation; D008262:Macrophage Activation; D008297:Male; D051379:Mice; D008809:Mice, Inbred C3H; D018375:Neutrophil Activation; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
D000970:Antineoplastic Agents; D008070:Lipopolysaccharides; D014409:Tumor Necrosis Factor-alpha